2022-500849-24-00招募中1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Executive Officer
Scientific
Tolremo Therapeutics AG
研究点 (3)
Loading locations...
相似试验
已完成
不适用
A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in subjects with cutaneous warts.cutaneous warts10014982NL-OMON41213Cutanea Life Sciences12
进行中（未招募）
不适用
A study in volunteers with cutaneous warts to assess safety and the effect of the body on topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide.Cutaneous wartsMedDRA version: 16.1Level: HLTClassification code 10033724Term: Papilloma viral infectionsSystem Organ Class: 100000004862EUCTR2013-005569-38-NLCutanea Life Sciences
进行中（未招募）
1 期
A first in-human study to evaluate safety, feasibility and efficacy of multiple dosing with individualised immunotherapy (VB10.NEO) or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockadeocally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHNMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10041823Term: Squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077840Term: Urothelial cancer of renal pelvisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002474-39-DEykode Therapeutics AS101
已完成
1 期
A Phase I, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of APL-2Renal and Urogenital - Kidney diseaseKidney DiseaseACTRN12617000822381Clinical Network Services Pty Ltd16
尚未招募
1 期
A Phase 1, Open Label, First in Human (FIH) Study Investigating Photodynamic Therapy (PDT) with INV043 0.5% Ointment in Adults with Non-melanoma Skin Cancerson melanoma skin cancerNon melanoma skin cancerCancer - Non melanoma skin cancerACTRN12624000310561Invion Limited150